Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has announced

The cause of amyotrophic lateral sclerosis (ALS) — a disabling neurodegenerative disease that affects nerve cells in the brain and spinal cord and leads to weakened muscles and early death

Our proprietary technology platform enables pharmaceutical companies to accelerate and improve the rate of drug discovery and development Through the development of epigenetic biomarkers, EpiSwitch™ can help pharmaceutical companies to: REDUCE the risk, cost and time to market for

EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”).  CCSs can provide a compelling, stable framework

Exercise appears to benefit people with amyotrophic lateral sclerosis (ALS) by normalizing molecular changes that occur at the junction of nerves and muscles, but by degrees that depend on the type of exercise,

Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers for the pharmaceutical and biotechnology industry, has announced that data yielded by application of its

Renowned immunologist Iain McInnes has been appointed to the Scientific Advisory Boar of Oxford BioDynamics Plc, where he joins Karol Sikora, Jane Mellor and Lucien Peng-Jin Ooi. McInnes is one

Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, has announced

History  The NHS describes motor neurone disease (MND) as: ‘An uncommon condition that affects the brain and nerves. It causes weakness that gets worse over time.’ The weakness is caused

Oxford BioDynamics (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, noted that